{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:55:59Z","timestamp":1793890559995,"version":"4.8.0"},"reference-count":144,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/100011722","name":"funding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,5,24]]},"DOI":"10.1080\/14656566.2022.2070429","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:15:39Z","timestamp":1650953739000},"page":"959-978","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Advances in biologic and small molecule therapies for hidradenitis suppurativa"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-4786","authenticated-orcid":false,"given":"Stella X.","family":"Chen","sequence":"first","affiliation":[{"name":"Harvard Combined Dermatology Residency Program","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Greif","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby S.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center","place":["Boston, USA"]},{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0479","authenticated-orcid":false,"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center","place":["Boston, USA"]},{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq031"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0749"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1492"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10698.x"},{"key":"e_1_3_4_14_1","volume-title":"Humira (Adalimumab) [Package Insert]","year":"2021","unstructured":"Humira (Adalimumab) [Package Insert]. North Chicago IL: AbbVie Inc.; 2021."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.370"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80164-9"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.1.S37"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10339.x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04638.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14997"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15605"},{"key":"e_1_3_4_25_1","volume-title":"Remicade (Infliximab) [Package Insert]","year":"2013","unstructured":"Remicade (Infliximab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2013."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.328"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00002"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000212"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48297"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12713"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.071"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.022"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.683767"},{"key":"e_1_3_4_35_1","volume-title":"Enbrel (Etanercept) [Package Insert]","year":"2020","unstructured":"Enbrel (Etanercept) [Package Insert]. Thousand Oaks CA: Immunex Corporation; 2020."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004273321"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/mjd.2003.554"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08372.x"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.898"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.72"},{"key":"e_1_3_4_41_1","volume-title":"Cimzia (Certolizumab Pegol) [Package Insert]","year":"2017","unstructured":"Cimzia (Certolizumab Pegol) [Package Insert]. Smyrna GA: UCB, Inc.; 2017."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i17.2591"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2018.042"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15286"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14494"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511284"},{"key":"e_1_3_4_48_1","volume-title":"Simponi (Golimumab) [Package Insert]","year":"2020","unstructured":"Simponi (Golimumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2020."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0217-6"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.04.026"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.218"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1924147"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13449"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_3_4_56_1","volume-title":"A Study to Test the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A Study to Test the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT). Identifier NCT04901195."},{"key":"e_1_3_4_57_1","volume-title":"A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II). Identifier NCT04242498."},{"key":"e_1_3_4_58_1","volume-title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I). Identifier NCT04242446."},{"key":"e_1_3_4_59_1","volume-title":"East Hanover","author":"Cosentyx (Secukinumab) [Package Insert]","year":"2021","unstructured":"Cosentyx (Secukinumab) [Package Insert]. East Hanover. New Jersey: Novartis Pharmaceuticals Corporation; 2021."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16605"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17178"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.005"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822"},{"key":"e_1_3_4_64_1","volume-title":"Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE). Identifier NCT03713632."},{"key":"e_1_3_4_65_1","volume-title":"This Is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. This Is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). SUNSHINE. Identifier NCT03713619."},{"key":"e_1_3_4_66_1","volume-title":"Extension Study to Assess Effects of Non-Interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Extension Study to Assess Effects of Non-Interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa. Identifier NCT04179175."},{"key":"e_1_3_4_67_1","volume-title":"Bridgewater, NJ: Valeant Pharmaceuticals","author":"Siliq (Brodalumab) [Package Insert]","year":"2017","unstructured":"Siliq (Brodalumab) [Package Insert]. Bridgewater, NJ: Valeant Pharmaceuticals. North America LLC; 2017."},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19478"},{"key":"e_1_3_4_70_1","volume-title":"Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa. Identifier NCT04979520."},{"key":"e_1_3_4_71_1","volume-title":"Treatment of Moderate Hidradenitis Suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Treatment of Moderate Hidradenitis Suppurativa. Identifier NCT03910803."},{"key":"e_1_3_4_72_1","volume-title":"Taltz (Ixekizumab)","year":"2016","unstructured":"Taltz (Ixekizumab). Package Insert. Indianapolis IN: Eli Lilly and Company; 2016."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16406"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.036"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13756"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17071"},{"key":"e_1_3_4_77_1","volume-title":"Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients. Identifier NCT02421172."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211035667"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"e_1_3_4_81_1","volume-title":"Tremfya (Guselkumab) [Package Insert]","year":"2020","unstructured":"Tremfya (Guselkumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2020."},{"key":"e_1_3_4_82_1","unstructured":"ClinicalTrials. Gov. A study to evaluate the efficacy safety and tolerability of guselkumab for the treatment of participants with moderate to severe Hidradenitis Suppurativa (HS) (NOVA). Identifier NCT03628924."},{"key":"e_1_3_4_83_1","volume-title":"Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (HiGUS). Identifier NCT04061395."},{"key":"e_1_3_4_84_1","volume-title":"Skyrizi (Risankizumab-Rzaa) [Package Insert]","year":"2021","unstructured":"Skyrizi (Risankizumab-Rzaa) [Package Insert]. North Chicago IL: AbbVie Inc.; 2021."},{"key":"e_1_3_4_85_1","unstructured":"ClinicalTrials. Gov. A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa (DETERMINED 1). Identifier NCT03926169."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15116"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.029"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15704"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19716"},{"key":"e_1_3_4_90_1","volume-title":"Ilumya (Tildrakizumab-Asmn) [Package Insert]","year":"2018","unstructured":"Ilumya (Tildrakizumab-Asmn) [Package Insert]. Whitehouse Station NJ: Merck & Co., Inc.; 2018."},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13559"},{"key":"e_1_3_4_92_1","volume-title":"Stelara (Ustekinumab) [Package Insert]","year":"2018","unstructured":"Stelara (Ustekinumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2018."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1776208"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1755008"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501075"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14054"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228436"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.030"},{"key":"e_1_3_4_102_1","volume-title":"A study to evaluate the efficacy, safety and tolerability of bermekimab in patients with hidradenitis suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A study to evaluate the efficacy, safety and tolerability of bermekimab in patients with hidradenitis suppurativa. Identifier NCT04019041."},{"key":"e_1_3_4_103_1","volume-title":"A study of bermekimab for the treatment of participants with moderate to severe hidradenitis suppurativa (LYRA)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A study of bermekimab for the treatment of participants with moderate to severe hidradenitis suppurativa (LYRA). Identifier NCT04988308."},{"key":"e_1_3_4_104_1","volume-title":"Kineret (Anakinra) [Package Insert]","year":"2016","unstructured":"Kineret (Anakinra) [Package Insert]. Stockholm Sweden: Swedish Orphan Biovitrum AB; 2016."},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.044"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"e_1_3_4_107_1","volume-title":"Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa. Identifier NCT01838499."},{"key":"e_1_3_4_108_1","volume-title":"Ilaris (Canakinumab) [Package Insert]","year":"2016","unstructured":"Ilaris (Canakinumab) [Package Insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2016."},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2018"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2392"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew208"},{"key":"e_1_3_4_112_1","volume-title":"Otezla (Apremilast) [Package Insert]","year":"2017","unstructured":"Otezla (Apremilast) [Package Insert]. Summit NJ: Celgene Corporation; 2017."},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.63.1.101"},{"issue":"2","key":"e_1_3_4_114_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.064691","article-title":"Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor","volume":"310","author":"Claveau D","year":"2004","unstructured":"Claveau D, Chen SL, O\u2019Keefe S, et al. Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor. J Pharmacol Exp Ther. 2004;310(2):752\u2013760.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.046"},{"issue":"2","key":"e_1_3_4_116_1","first-page":"170","article-title":"Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study","volume":"18","author":"Kerdel FR","year":"2019","unstructured":"Kerdel FR, Azevedo FA, Kerdel Don C, et al. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J Drugs Dermatol. 2019;18(2):170\u2013176.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_117_1","unstructured":"UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis. PR Newswire (Online). Published November 4 2021. Accessed December 2 2021. https:\/\/www.prnewswire.com\/news-releases\/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301416168.html"},{"key":"e_1_3_4_118_1","volume-title":"Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS). Identifier NCT04982432."},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.267"},{"key":"e_1_3_4_121_1","unstructured":"ClinicalTrials. Gov. A study of the safety of INCB054707 in participants with hidradenitis suppurativa. identifier NCT03569371."},{"key":"e_1_3_4_122_1","unstructured":"ClinicalTrials. Gov. A placebo-controlled study of the safety of INCB054707 in participants with hidradenitis suppurativa. Identifier NCT03607487."},{"key":"e_1_3_4_123_1","volume-title":"To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa. Identifier NCT04476043."},{"key":"e_1_3_4_124_1","volume-title":"Rinvoq (Upadacitinib) [Package Insert]","year":"2019","unstructured":"Rinvoq (Upadacitinib) [Package Insert]. North Chicago IL: Abbvie Inc.; 2019."},{"key":"e_1_3_4_125_1","unstructured":"RINVOQ\u00ae (upadacitinib) Receives U.S. FDA approval for active psoriatic arthritis. Published December 14 2021. Accessed December 16 2021. https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-receives-us-fda-approval-for-active-psoriatic-arthritis.htm"},{"key":"e_1_3_4_126_1","volume-title":"A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms. Identifier NCT04430855."},{"key":"e_1_3_4_127_1","volume-title":"Xeljanz (Tofacitinib) [Package Insert]","year":"2018","unstructured":"Xeljanz (Tofacitinib) [Package Insert]. New York NY: Pfizer, Inc.; 2018."},{"key":"e_1_3_4_128_1","unstructured":"U.S. FDA approves pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the treatment of active ankylosing spondylitis. Published December 14 2021. Accessed December 16 2021. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.10.010"},{"key":"e_1_3_4_130_1","volume-title":"Tofacitinib for Immune Skin Conditions in Down Syndrome","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. Tofacitinib for Immune Skin Conditions in Down Syndrome. Identifier NCT04246372."},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01082-y"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1567713"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_4_135_1","volume-title":"A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa","author":"ClinicalTrials. Gov","unstructured":"ClinicalTrials. Gov. A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa. Identifier NCT04092452."},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00009"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14056"},{"key":"e_1_3_4_138_1","volume-title":"Tavneos (Avacopan) [Package Insert]","year":"2021","unstructured":"Tavneos (Avacopan) [Package Insert]. Cincinnati OH: ChemoCentryx Inc.; 2021."},{"key":"e_1_3_4_139_1","volume-title":"Evaluation of safety and efficacy of avacopan in subjects with moderate to severe hidradenitis suppurativa (Aurora)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. Evaluation of safety and efficacy of avacopan in subjects with moderate to severe hidradenitis suppurativa (Aurora). Identifier NCT03852472."},{"key":"e_1_3_4_140_1","unstructured":"ChemoCentryx Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS). ChemoCentryx. October 20 2020. www.ir.chemocentryx.com\/news-releases\/news-release-details\/chemocentryx-announces-positive-topline-results-phase-ii-aurora. Press release."},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18877"},{"key":"e_1_3_4_142_1","unstructured":"InflaRx reports additional analysis of the SHINE Phase IIb results for IFX-1 in hidradenitis suppurativa. InflaRx. Press release. July 18 2019; www.inflarx.de\/Home\/Investors\/Press-Releases\/07-2019-InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa-.html"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13798"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.068"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508787"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2070429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:08:21Z","timestamp":1772719701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2070429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,5,24]]}},"alternative-id":["10.1080\/14656566.2022.2070429"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2070429","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}